RxDoctor Payments Data

Raymond Khargi, MD

Urology · Brooklyn, NYNPI 1841726486

Payments from drug & device makers

$35,033in general payments, 2019–2025

Across 98 payments — averaging $357.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$34K
  • Sumitomo Pharma America, Inc.$283
  • Urogen Pharma, Inc.$154
  • Calyxo, Inc.$151
  • Cook Medical LLC$123
  • Medtronic$119
  • plus $564 from 13 others

What the payments were for

  • Grants$30,00086%
  • Travel & lodging$7852%
  • Food & beverage$4,21612%
  • Education$330%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,033 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$64,815
Medicare patients
166
Services billed
607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron16$20,329
GemtesaVibegron24$13,028
Potassium Citrate ErPotassium Citrate121$12,731
Tamsulosin Hcl138$2,119
Finasteride30$503
Alfuzosin Hcl ErAlfuzosin Hcl23$368
Chlorthalidone20$294
Oxybutynin Chloride ErOxybutynin Chloride25$267
Ciprofloxacin Hcl34$155
Cephalexin14$81
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$43$20,32916 claims
Sumitomo Pharma America, Inc.Gemtesa$283$13,02824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.

Other urology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →